26
|
Hall P, Howell S, Venkitaraman R, Thomson A, Raja F, King J, Michie C, Khan S, Brunt A, Gahir D, McAdam K, Cooner J, Kane N. P084 Socioeconomic Outcomes With Ribociclib in Patients With HR+, HER2– Advanced Breast Cancer (ABC) in UK Real-world Settings. Breast 2023. [DOI: 10.1016/s0960-9776(23)00201-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/18/2023] Open
|
27
|
Girardi F, Matz M, Stiller C, You H, Marcos Gragera R, Valkov MY, Bulliard JL, De P, Morrison D, Wanner M, O'Brian DK, Saint-Jacques N, Coleman MP, Allemani C, Hamdi-Chérif M, Kara L, Meguenni K, Regagba D, Bayo S, Cheick Bougadari T, Manraj SS, Bendahhou K, Ladipo A, Ogunbiyi OJ, Somdyala NIM, Chaplin MA, Moreno F, Calabrano GH, Espinola SB, Carballo Quintero B, Fita R, Laspada WD, Ibañez SG, Lima CA, Da Costa AM, De Souza PCF, Chaves J, Laporte CA, Curado MP, de Oliveira JC, Veneziano CLA, Veneziano DB, Almeida ABM, Latorre MRDO, Rebelo MS, Santos MO, Azevedo e Silva G, Galaz JC, Aparicio Aravena M, Sanhueza Monsalve J, Herrmann DA, Vargas S, Herrera VM, Uribe CJ, Bravo LE, Garcia LS, Arias-Ortiz NE, Morantes D, Jurado DM, Yépez Chamorro MC, Delgado S, Ramirez M, Galán Alvarez YH, Torres P, Martínez-Reyes F, Jaramillo L, Quinto R, Castillo J, Mendoza M, Cueva P, Yépez JG, Bhakkan B, Deloumeaux J, Joachim C, Macni J, Carrillo R, Shalkow Klincovstein J, Rivera Gomez R, Perez P, Poquioma E, Tortolero-Luna G, Zavala D, Alonso R, Barrios E, Eckstrand A, Nikiforuk C, Woods RR, Noonan G, Turner D, Kumar E, Zhang B, Dowden JJ, Doyle GP, Saint-Jacques N, Walsh G, Anam A, De P, McClure CA, Vriends KA, Bertrand C, Ramanakumar AV, Davis L, Kozie S, Freeman T, George JT, Avila RM, O’Brien DK, Holt A, Almon L, Kwong S, Morris C, Rycroft R, Mueller L, Phillips CE, Brown H, Cromartie B, Ruterbusch J, Schwartz AG, Levin GM, Wohler B, Bayakly R, Ward KC, Gomez SL, McKinley M, Cress R, Davis J, Hernandez B, Johnson CJ, Morawski BM, Ruppert LP, Bentler S, Charlton ME, Huang B, Tucker TC, Deapen D, Liu L, Hsieh MC, Wu XC, Schwenn M, Stern K, Gershman ST, Knowlton RC, Alverson G, Weaver T, Desai J, Rogers DB, Jackson-Thompson J, Lemons D, Zimmerman HJ, Hood M, Roberts-Johnson J, Hammond W, Rees JR, Pawlish KS, Stroup A, Key C, Wiggins C, Kahn AR, Schymura MJ, Radhakrishnan S, Rao C, Giljahn LK, Slocumb RM, Dabbs C, Espinoza RE, Aird KG, Beran T, Rubertone JJ, Slack SJ, Oh J, Janes TA, Schwartz SM, Chiodini SC, Hurley DM, Whiteside MA, Rai S, Williams MA, Herget K, Sweeney C, Kachajian J, Keitheri Cheteri MB, Migliore Santiago P, Blankenship SE, Conaway JL, Borchers R, Malicki R, Espinoza J, Grandpre J, Weir HK, Wilson R, Edwards BK, Mariotto A, Rodriguez-Galindo C, Wang N, Yang L, Chen JS, Zhou Y, He YT, Song GH, Gu XP, Mei D, Mu HJ, Ge HM, Wu TH, Li YY, Zhao DL, Jin F, Zhang JH, Zhu FD, Junhua Q, Yang YL, Jiang CX, Biao W, Wang J, Li QL, Yi H, Zhou X, Dong J, Li W, Fu FX, Liu SZ, Chen JG, Zhu J, Li YH, Lu YQ, Fan M, Huang SQ, Guo GP, Zhaolai H, Wei K, Chen WQ, Wei W, Zeng H, Demetriou AV, Mang WK, Ngan KC, Kataki AC, Krishnatreya M, Jayalekshmi PA, Sebastian P, George PS, Mathew A, Nandakumar A, Malekzadeh R, Roshandel G, Keinan-Boker L, Silverman BG, Ito H, Koyanagi Y, Sato M, Tobori F, Nakata I, Teramoto N, Hattori M, Kaizaki Y, Moki F, Sugiyama H, Utada M, Nishimura M, Yoshida K, Kurosawa K, Nemoto Y, Narimatsu H, Sakaguchi M, Kanemura S, Naito M, Narisawa R, Miyashiro I, Nakata K, Mori D, Yoshitake M, Oki I, Fukushima N, Shibata A, Iwasa K, Ono C, Matsuda T, Nimri O, Jung KW, Won YJ, Alawadhi E, Elbasmi A, Ab Manan A, Adam F, Nansalmaa E, Tudev U, Ochir C, Al Khater AM, El Mistiri MM, Lim GH, Teo YY, Chiang CJ, Lee WC, Buasom R, Sangrajrang S, Suwanrungruang K, Vatanasapt P, Daoprasert K, Pongnikorn D, Leklob A, Sangkitipaiboon S, Geater SL, Sriplung H, Ceylan O, Kög I, Dirican O, Köse T, Gurbuz T, Karaşahin FE, Turhan D, Aktaş U, Halat Y, Eser S, Yakut CI, Altinisik M, Cavusoglu Y, Türkköylü A, Üçüncü N, Hackl M, Zborovskaya AA, Aleinikova OV, Henau K, Van Eycken L, Atanasov TY, Valerianova Z, Šekerija M, Dušek L, Zvolský M, Steinrud Mørch L, Storm H, Wessel Skovlund C, Innos K, Mägi M, Malila N, Seppä K, Jégu J, Velten M, Cornet E, Troussard X, Bouvier AM, Guizard AV, Bouvier V, Launoy G, Dabakuyo Yonli S, Poillot ML, Maynadié M, Mounier M, Vaconnet L, Woronoff AS, Daoulas M, Robaszkiewicz M, Clavel J, Poulalhon C, Desandes E, Lacour B, Baldi I, Amadeo B, Coureau G, Monnereau A, Orazio S, Audoin M, D’Almeida TC, Boyer S, Hammas K, Trétarre B, Colonna M, Delafosse P, Plouvier S, Cowppli-Bony A, Molinié F, Bara S, Ganry O, Lapôtre-Ledoux B, Daubisse-Marliac L, Bossard N, Uhry Z, Estève J, Stabenow R, Wilsdorf-Köhler H, Eberle A, Luttmann S, Löhden I, Nennecke AL, Kieschke J, Sirri E, Justenhoven C, Reinwald F, Holleczek B, Eisemann N, Katalinic A, Asquez RA, Kumar V, Petridou E, Ólafsdóttir EJ, Tryggvadóttir L, Murray DE, Walsh PM, Sundseth H, Harney M, Mazzoleni G, Vittadello F, Coviello E, Cuccaro F, Galasso R, Sampietro G, Giacomin A, Magoni M, Ardizzone A, D’Argenzio A, Di Prima AA, Ippolito A, Lavecchia AM, Sutera Sardo A, Gola G, Ballotari P, Giacomazzi E, Ferretti S, Dal Maso L, Serraino D, Celesia MV, Filiberti RA, Pannozzo F, Melcarne A, Quarta F, Andreano A, Russo AG, Carrozzi G, Cirilli C, Cavalieri d’Oro L, Rognoni M, Fusco M, Vitale MF, Usala M, Cusimano R, Mazzucco W, Michiara M, Sgargi P, Boschetti L, Marguati S, Chiaranda G, Seghini P, Maule MM, Merletti F, Spata E, Tumino R, Mancuso P, Cassetti T, Sassatelli R, Falcini F, Giorgetti S, Caiazzo AL, Cavallo R, Piras D, Bella F, Madeddu A, Fanetti AC, Maspero S, Carone S, Mincuzzi A, Candela G, Scuderi T, Gentilini MA, Rizzello R, Rosso S, Caldarella A, Intrieri T, Bianconi F, Contiero P, Tagliabue G, Rugge M, Zorzi M, Beggiato S, Brustolin A, Gatta G, De Angelis R, Vicentini M, Zanetti R, Stracci F, Maurina A, Oniščuka M, Mousavi M, Steponaviciene L, Vincerževskienė I, Azzopardi MJ, Calleja N, Siesling S, Visser O, Johannesen TB, Larønningen S, Trojanowski M, Macek P, Mierzwa T, Rachtan J, Rosińska A, Kępska K, Kościańska B, Barna K, Sulkowska U, Gebauer T, Łapińska JB, Wójcik-Tomaszewska J, Motnyk M, Patro A, Gos A, Sikorska K, Bielska-Lasota M, Didkowska JA, Wojciechowska U, Forjaz de Lacerda G, Rego RA, Carrito B, Pais A, Bento MJ, Rodrigues J, Lourenço A, Mayer-da-Silva A, Coza D, Todescu AI, Valkov MY, Gusenkova L, Lazarevich O, Prudnikova O, Vjushkov DM, Egorova A, Orlov A, Pikalova LV, Zhuikova LD, Adamcik J, Safaei Diba C, Zadnik V, Žagar T, De-La-Cruz M, Lopez-de-Munain A, Aleman A, Rojas D, Chillarón RJ, Navarro AIM, Marcos-Gragera R, Puigdemont M, Rodríguez-Barranco M, Sánchez Perez MJ, Franch Sureda P, Ramos Montserrat M, Chirlaque López MD, Sánchez Gil A, Ardanaz E, Guevara M, Cañete-Nieto A, Peris-Bonet R, Carulla M, Galceran J, Almela F, Sabater C, Khan S, Pettersson D, Dickman P, Staehelin K, Struchen B, Egger Hayoz C, Rapiti E, Schaffar R, Went P, Mousavi SM, Bulliard JL, Maspoli-Conconi M, Kuehni CE, Redmond SM, Bordoni A, Ortelli L, Chiolero A, Konzelmann I, Rohrmann S, Wanner M, Broggio J, Rashbass J, Stiller C, Fitzpatrick D, Gavin A, Morrison DS, Thomson CS, Greene G, Huws DW, Grayson M, Rawcliffe H, Allemani C, Coleman MP, Di Carlo V, Girardi F, Matz M, Minicozzi P, Sanz N, Ssenyonga N, James D, Stephens R, Chalker E, Smith M, Gugusheff J, You H, Qin Li S, Dugdale S, Moore J, Philpot S, Pfeiffer R, Thomas H, Silva Ragaini B, Venn AJ, Evans SM, Te Marvelde L, Savietto V, Trevithick R, Aitken J, Currow D, Fowler C, Lewis C. Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). Neuro Oncol 2023; 25:580-592. [PMID: 36355361 PMCID: PMC10013649 DOI: 10.1093/neuonc/noac217] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology. METHODS We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator. RESULTS The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults. CONCLUSIONS To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.
Collapse
|
28
|
Ali F, Ali S, Mohamed S, Khan I, Khan I, Khan S, Khan F, Alfeel AH, Higazi H. Analysis of mitochondrial DNA mutations in Pakistani population diagnosed with cardiovascular diseases. BRAZ J BIOL 2023; 84:e266924. [PMID: 36856233 DOI: 10.1590/1519-6984.266924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Accepted: 11/29/2022] [Indexed: 03/02/2023] Open
Abstract
Heart and blood vessel disorders, such as coronary heart disease, brain vessel disease, rheumatic heart disease, and others, are together referred to as cardiovascular disease (CVD). In this study, we sought to determine how mitochondrial Leucine Transfer RNA genes and CVDs are related (MT-L1 and MT-L2). From CVD patients in Peshawar, a total of 27 saliva samples were taken. Leu-tRNA genes expressed by mitochondria were amplified using polymerase chain reaction after DNA was removed. Ten samples were sent for sequencing after PCR and gene cleaning. We obtained all of the sequenced results, which were subsequently aligned and evaluated against the mitochondrial revised Cambridge Reference Sequence (rCRS). However, in our sequenced samples, Leu-tRNA MT-L1 and MT-L2 genes were determined to be unaltered. Thus, it is suggested that a large population be taken into account while screening for mutations in the mitochondrial encoded Leu-tRNA MT-L1 and MT-L2 genes of cardiac patients in areas of Pakistan. Additionally, it is recommended that patients with cardiac problems should also have other mitochondrial encoded genes checked for potential mutations. This could result in the identification of genetic markers that could be used for early CVD screening in Pakistan.
Collapse
|
29
|
Khan S, Rafiq K, Khabir MN, Khan MB, Khan SN, Khattak A, Attaullah S. Toxoplasma gondii in lactating animals: potential risk to milk consuming population in Khyber Pakhtunkhwa. BRAZ J BIOL 2023; 83:e267369. [PMID: 36790276 DOI: 10.1590/1519-6984.267369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Accepted: 01/15/2023] [Indexed: 02/16/2023] Open
Abstract
Toxoplasma gondii is an intracellular zoonotic protozoan parasite usually infects human and animal worldwide. This study aimed to analyze the sero-prevalence of T. gondii in blood of lactating animals and human living in close proximity and also to detect Toxoplasma DNA in unpasteurized milk of the studied animals. A total of 233 blood and milk samples were collected from lactating animals, and 735 blood samples were taken from humans in District Upper Dir, Khyber Pakhtunkhwa, Pakistan. The blood samples were analyzed through ELISA while the milk samples were analyzed by PCR for the presence of T. gondii DNA. A standard questionnaire was introduced to collect the data from the participants. In animals, the reported sero-prevalence was 32.18% for IgM, 17.16% for IgG, and 6.4% for both IgM and IgG. The reported positivity for T. gondii DNA in milk was 14.44%, 34.8%, 20%, and 26% in sheep, goats, cows, and buffaloes, respectively. In the human blood samples, 9.8% were found positive for IgM and 11.2% for IgG while none of the samples was found positive for both IgM and IgG. Overall sero-prevalence reported in females was significantly higher than the male (p<0.05) poor hygiene condition (p < 0.0001) were the significant risk factors associated with T. gondii infections in animals. In conclusion, T. gondii infection is prevalent in lactating animals and humans using their raw milk in the study area. It is suggested that raw milk should be considered as a vehicle for the transmission of T. gondii to humans. Proper pasteurization of milk is very useful in limiting the transmission of infection. Awareness and control programs should be implemented to prevent the infection.
Collapse
|
30
|
Roaldsen MB, Eltoft A, Wilsgaard T, Christensen H, Engelter ST, Indredavik B, Jatužis D, Karelis G, Kõrv J, Lundström E, Petersson J, Putaala J, Søyland MH, Tveiten A, Bivard A, Johnsen SH, Mazya MV, Werring DJ, Wu TY, De Marchis GM, Robinson TG, Mathiesen EB, Valente M, Chen A, Sharobeam A, Edwards L, Blair C, Christensen L, Ægidius K, Pihl T, Fassel-Larsen C, Wassvik L, Folke M, Rosenbaum S, Gharehbagh SS, Hansen A, Preisler N, Antsov K, Mallene S, Lill M, Herodes M, Vibo R, Rakitin A, Saarinen J, Tiainen M, Tumpula O, Noppari T, Raty S, Sibolt G, Nieminen J, Niederhauser J, Haritoncenko I, Puustinen J, Haula TM, Sipilä J, Viesulaite B, Taroza S, Rastenyte D, Matijosaitis V, Vilionskis A, Masiliunas R, Ekkert A, Chmeliauskas P, Lukosaitis V, Reichenbach A, Moss TT, Nilsen HY, Hammer-Berntzen R, Nordby LM, Weiby TA, Nordengen K, Ihle-Hansen H, Stankiewiecz M, Grotle O, Nes M, Thiemann K, Særvold IM, Fraas M, Størdahl S, Horn JW, Hildrum H, Myrstad C, Tobro H, Tunvold JA, Jacobsen O, Aamodt N, Baisa H, Malmberg VN, Rohweder G, Ellekjær H, Ildstad F, Egstad E, Helleberg BH, Berg HH, Jørgensen J, Tronvik E, Shirzadi M, Solhoff R, Van Lessen R, Vatne A, Forselv K, Frøyshov H, Fjeldstad MS, Tangen L, Matapour S, Kindberg K, Johannessen C, Rist M, Mathisen I, Nyrnes T, Haavik A, Toverud G, Aakvik K, Larsson M, Ytrehus K, Ingebrigtsen S, Stokmo T, Helander C, Larsen IC, Solberg TO, Seljeseth YM, Maini S, Bersås I, Mathé J, Rooth E, Laska AC, Rudberg AS, Esbjörnsson M, Andler F, Ericsson A, Wickberg O, Karlsson JE, Redfors P, Jood K, Buchwald F, Mansson K, Gråhamn O, Sjölin K, Lindvall E, Cidh Å, Tolf A, Fasth O, Hedström B, Fladt J, Dittrich TD, Kriemler L, Hannon N, Amis E, Finlay S, Mitchell-Douglas J, McGee J, Davies R, Johnson V, Nair A, Robinson M, Greig J, Halse O, Wilding P, Mashate S, Chatterjee K, Martin M, Leason S, Roberts J, Dutta D, Ward D, Rayessa R, Clarkson E, Teo J, Ho C, Conway S, Aissa M, Papavasileiou V, Fry S, Waugh D, Britton J, Hassan A, Manning L, Khan S, Asaipillai A, Fornolles C, Tate ML, Chenna S, Anjum T, Karunatilake D, Foot J, VanPelt L, Shetty A, Wilkes G, Buck A, Jackson B, Fleming L, Carpenter M, Jackson L, Needle A, Zahoor T, Duraisami T, Northcott K, Kubie J, Bowring A, Keenan S, Mackle D, England T, Rushton B, Hedstrom A, Amlani S, Evans R, Muddegowda G, Remegoso A, Ferdinand P, Varquez R, Davis M, Elkin E, Seal R, Fawcett M, Gradwell C, Travers C, Atkinson B, Woodward S, Giraldo L, Byers J, Cheripelli B, Lee S, Marigold R, Smith S, Zhang L, Ghatala R, Sim CH, Ghani U, Yates K, Obarey S, Willmot M, Ahlquist K, Bates M, Rashed K, Board S, Andsberg G, Sundayi S, Garside M, Macleod MJ, Manoj A, Hopper O, Cederin B, Toomsoo T, Gross-Paju K, Tapiola T, Kestutis J, Amthor KF, Heermann B, Ottesen V, Melum TA, Kurz M, Parsons M, Valente M, Chen A, Sharobeam A, Edwards L, Blair C. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial. Lancet Neurol 2023; 22:117-126. [PMID: 36549308 DOI: 10.1016/s1474-4422(22)00484-7] [Citation(s) in RCA: 20] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 11/18/2022] [Accepted: 11/21/2022] [Indexed: 12/24/2022]
Abstract
BACKGROUND Current evidence supports the use of intravenous thrombolysis with alteplase in patients with wake-up stroke selected with MRI or perfusion imaging and is recommended in clinical guidelines. However, access to advanced imaging techniques is often scarce. We aimed to determine whether thrombolytic treatment with intravenous tenecteplase given within 4·5 h of awakening improves functional outcome in patients with ischaemic wake-up stroke selected using non-contrast CT. METHODS TWIST was an investigator-initiated, multicentre, open-label, randomised controlled trial with blinded endpoint assessment, conducted at 77 hospitals in ten countries. We included patients aged 18 years or older with acute ischaemic stroke symptoms upon awakening, limb weakness, a National Institutes of Health Stroke Scale (NIHSS) score of 3 or higher or aphasia, a non-contrast CT examination of the head, and the ability to receive tenecteplase within 4·5 h of awakening. Patients were randomly assigned (1:1) to either a single intravenous bolus of tenecteplase 0·25 mg per kg of bodyweight (maximum 25 mg) or control (no thrombolysis) using a central, web-based, computer-generated randomisation schedule. Trained research personnel, who conducted telephone interviews at 90 days (follow-up), were masked to treatment allocation. Clinical assessments were performed on day 1 (at baseline) and day 7 of hospital admission (or at discharge, whichever occurred first). The primary outcome was functional outcome assessed by the modified Rankin Scale (mRS) at 90 days and analysed using ordinal logistic regression in the intention-to-treat population. This trial is registered with EudraCT (2014-000096-80), ClinicalTrials.gov (NCT03181360), and ISRCTN (10601890). FINDINGS From June 12, 2017, to Sept 30, 2021, 578 of the required 600 patients were enrolled (288 randomly assigned to the tenecteplase group and 290 to the control group [intention-to-treat population]). The median age of participants was 73·7 years (IQR 65·9-81·1). 332 (57%) of 578 participants were male and 246 (43%) were female. Treatment with tenecteplase was not associated with better functional outcome, according to mRS score at 90 days (adjusted OR 1·18, 95% CI 0·88-1·58; p=0·27). Mortality at 90 days did not significantly differ between treatment groups (28 [10%] patients in the tenecteplase group and 23 [8%] in the control group; adjusted HR 1·29, 95% CI 0·74-2·26; p=0·37). Symptomatic intracranial haemorrhage occurred in six (2%) patients in the tenecteplase group versus three (1%) in the control group (adjusted OR 2·17, 95% CI 0·53-8·87; p=0·28), whereas any intracranial haemorrhage occurred in 33 (11%) versus 30 (10%) patients (adjusted OR 1·14, 0·67-1·94; p=0·64). INTERPRETATION In patients with wake-up stroke selected with non-contrast CT, treatment with tenecteplase was not associated with better functional outcome at 90 days. The number of symptomatic haemorrhages and any intracranial haemorrhages in both treatment groups was similar to findings from previous trials of wake-up stroke patients selected using advanced imaging. Current evidence does not support treatment with tenecteplase in patients selected with non-contrast CT. FUNDING Norwegian Clinical Research Therapy in the Specialist Health Services Programme, the Swiss Heart Foundation, the British Heart Foundation, and the Norwegian National Association for Public Health.
Collapse
|
31
|
Montandon S, Win S, Jones S, Bello I, Amin A, Khan S, Biswas S, Aperios G, Gibson M, Yahia G. 1255 IMPROVING COMMUNICATION BETWEEN NEXT OF KIN AND MEDICAL STAFF FOR OUR MOST VULNERABLE PATIENTS: A QUALITY IMPROVEMENT PROJECT. Age Ageing 2023. [DOI: 10.1093/ageing/afac322.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
Abstract
Abstract
Background
This project was completed by a team of junior doctors working across two general medical wards at Queen Alexandra Hospital.
Introduction
Due to persistently high bed occupancy, patients are increasingly subject to multiple moves, increasing the risk of missed or delayed communication (Toye C et al, Clin interv aging, 2019, 14, 2223-2237). Importantly, families who receive good communication from staff are more likely to feel satisfied with the care of their loved one (Ersek M et al, J pain symptom manage, 2021, 62(2), 213–222). Our aim was to increase the occurrence and comprehensiveness of documented discussions between next of kin (NOK) and the medical team, especially in vulnerable patients who may be unable to advocate for themselves.
Methods
We conducted a retrospective, cross-sectional analysis of patient notes across two PDSA cycles. NICE guidelines NG27, NG97 and NG96 provided an audit standard. Patients were identified as at-risk of poor communication if diagnosed with dementia, cognitive impairment, addiction, learning difficulties or needing an interpreter. Targeted intervention prior to re-audit included education of the medical team and introduction of a written prompt within the patient’s notes.
Results
25/55 patients were identified as at-risk in cycle one, with 39/71 patients at-risk in cycle two. Post-intervention, the number of at-risk patients with a documented NOK discussion increased from 74% to 82%. Patient treatment plan discussions increased from 81% to 97%. Discussions, where applicable, regarding escalation of care, Deprivation of Liberty Safeguards (DoLS), capacity and Mental Health Act (MHA) slightly decreased. Conversations regarding patient consent for data sharing were rarely documented.
Conclusion
Our intervention increased the proportion of documented patient discussions; however, it did highlight the need to improve the frequency of documented conversations surrounding escalation of care, DoLS, capacity and MHA. This has provided impetus for further improvement projects.
Collapse
|
32
|
Khattak A, Khan S, Ali I, Gul A, Khabir MN, Javed B, Adnan M, Khan SN, Attaullah S. Burden and distribution of dengue infection in Pakistan (2000-19): a review. BRAZ J BIOL 2023; 84:e267982. [PMID: 37075435 DOI: 10.1590/1519-6984.267982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Accepted: 02/22/2023] [Indexed: 04/21/2023] Open
Abstract
The goal of this study is to review the overall prevalence, burden, and distribution of the dengue disease in Pakistan from 2000 to 2019. Literature was searched using different search engines like Google scholar, PubMed, etc. providing the keywords "Dengue disease/infection, Dengue virus, DENV, DF/DHF/ DSS Pakistan". All the published research papers/reports on the dengue virus over the period 2000 to 2019 were studied and selected data were summarized using MS Excel for windows such as total cases, age wise, gender, DENV serotype distribution, total DHF, and DSS patients. The literature providing insufficient data was excluded. The total number of cases reported during 2000-19 were 201,269. The maximum number of cases during the mentioned literature survey period was reported in Khyber Pakhtunkhwa (KP) (23.3%) followed by Punjab (3.8%) and Sindh (1.9%). The majority of dengue-infected cases were reported as Dengue fever (74.4%) followed by DHF (24.1%) and DSS (1.5%). Overall the deaths during the mentioned literature survey were 1082, of which the maximum mortalities were reported from KP (N=248) followed by Punjab (N=220). DENV remains a major public health problem in Pakistan and seems to remain endemic for a long time. The total prevalence of dengue infection is increased accordingly with time from 2000 to 2019. Moreover, all the four serotypes exist in Pakistan with increased mortalities.
Collapse
|
33
|
Baker KL, MacLaren S, Jones O, Spears BK, Patel PK, Nora R, Divol L, Landen OL, Anderson GJ, Gaffney J, Kruse M, Hurricane OA, Callahan DA, Christopherson AR, Salmonson J, Hartouni EP, Döppner T, Dewald E, Tommasini R, Thomas CA, Weber C, Clark D, Casey DT, Hohenberger M, Khan S, Woods T, Milovich JL, Berger RL, Strozzi D, Kritcher A, Bachmann B, Benedetti R, Bionta R, Celliers PM, Fittinghoff D, Hatarik R, Izumi N, Gatu Johnson M, Kyrala G, Ma T, Meaney K, Millot M, Nagel SR, Pak A, Volegov PL, Yeamans C, Wilde C. Alpha heating of indirect-drive layered implosions on the National Ignition Facility. Phys Rev E 2023; 107:015202. [PMID: 36797905 DOI: 10.1103/physreve.107.015202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Accepted: 11/30/2022] [Indexed: 01/11/2023]
Abstract
In order to understand how close current layered implosions in indirect-drive inertial confinement fusion are to ignition, it is necessary to measure the level of alpha heating present. To this end, pairs of experiments were performed that consisted of a low-yield tritium-hydrogen-deuterium (THD) layered implosion and a high-yield deuterium-tritium (DT) layered implosion to validate experimentally current simulation-based methods of determining yield amplification. The THD capsules were designed to reduce simultaneously DT neutron yield (alpha heating) and maintain hydrodynamic similarity with the higher yield DT capsules. The ratio of the yields measured in these experiments then allowed the alpha heating level of the DT layered implosions to be determined. The level of alpha heating inferred is consistent with fits to simulations expressed in terms of experimentally measurable quantities and enables us to infer the level of alpha heating in recent high-performing implosions.
Collapse
|
34
|
Bachmann B, MacLaren SA, Bhandarkar S, Briggs T, Casey D, Divol L, Döppner T, Fittinghoff D, Freeman M, Haan S, Hall GN, Hammel B, Hartouni E, Izumi N, Geppert-Kleinrath V, Khan S, Kozioziemski B, Krauland C, Landen O, Mariscal D, Marley E, Masse L, Meaney K, Mellos G, Moore A, Pak A, Patel P, Ratledge M, Rice N, Rubery M, Salmonson J, Sater J, Schlossberg D, Schneider M, Smalyuk VA, Trosseille C, Volegov P, Weber C, Williams GJ, Wray A. Measurement of Dark Ice-Ablator Mix in Inertial Confinement Fusion. PHYSICAL REVIEW LETTERS 2022; 129:275001. [PMID: 36638294 DOI: 10.1103/physrevlett.129.275001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/19/2022] [Accepted: 11/29/2022] [Indexed: 06/17/2023]
Abstract
We present measurements of ice-ablator mix at stagnation of inertially confined, cryogenically layered capsule implosions. An ice layer thickness scan with layers significantly thinner than used in ignition experiments enables us to investigate mix near the inner ablator interface. Our experiments reveal for the first time that the majority of atomically mixed ablator material is "dark" mix. It is seeded by the ice-ablator interface instability and located in the relatively cooler, denser region of the fuel assembly surrounding the fusion hot spot. The amount of dark mix is an important quantity as it is thought to affect both fusion fuel compression and burn propagation when it turns into hot mix as the burn wave propagates through the initially colder fuel region surrounding an igniting hot spot. We demonstrate a significant reduction in ice-ablator mix in the hot-spot boundary region when we increase the initial ice layer thickness.
Collapse
|
35
|
Solanky S, Khan S, Ejarque RA, Tosi I, Dawe H, Barker J, Di Meglio P, Consortium P. 096 IL23-induced STAT3 nuclear translocation in MAIT cells at baseline is a candidate biomarker of response to biologics targeting the IL23/IL17 axis. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
36
|
Martinelli E, Cremolini C, Mazard T, Vidal J, Virchow I, Tougeron D, Cuyle PJ, Chibaudel B, Kim S, Ghanem I, Asselain B, Castagné C, Zkik A, Khan S, Arnold D. Real-world first-line treatment of patients with BRAF V600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study. ESMO Open 2022; 7:100603. [PMID: 36368253 PMCID: PMC9832736 DOI: 10.1016/j.esmoop.2022.100603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Revised: 09/20/2022] [Accepted: 09/21/2022] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND BRAFV600E mutations occur in 8%-12% of metastatic colorectal cancer (mCRC) cases and are associated with poor survival. European guidelines recommend combination (doublet or triplet) chemotherapy plus bevacizumab in first line. However, an unmet need remains for more effective treatments for these patients. PATIENTS AND METHODS CAPSTAN CRC is a European, retrospective, multicenter, observational study evaluating real-world treatment practices for patients with BRAFV600E-mutant mCRC treated between 1 January 2016 and 31 January 2020. The primary objective was to describe first-line treatment patterns. Secondary objectives included describing baseline demographics, mutational testing procedures, treatment effectiveness, and safety. RESULTS In total, 255 patients (median age 66.0 years; 58.4% female) with BRAFV600E-mutant unresectable mCRC from seven countries were included. Most had right-sided tumors (52.5%) and presented with synchronous disease at diagnosis (66.4%). Chemotherapy plus targeted therapy (68.7%) was preferred at first line over chemotherapy alone (31.3%). The main first-line treatments were FOLFOX plus bevacizumab (27.1%) and FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin, irinotecan) with/without bevacizumab (27.1%/19.2%). Median duration of first-line treatment was 4.9 months. Overall, 52.5% received second-line treatment. Across all first-line regimens, progression-free survival (PFS) and overall survival were 6.0 [95% confidence interval (CI) 5.3-6.7] months and 12.9 (95% CI 11.6-14.1) months, respectively. Triplet plus targeted therapy was associated with more adverse events (75.0%) compared with triplet chemotherapy alone (50.0%) and doublet chemotherapy alone (36.1%). Multivariate analysis identified low body mass index and presence of three or more metastatic sites as significant prognostic factors for PFS. CONCLUSIONS This study is, to date, the largest real-world analysis of patients with BRAFV600E-mutant mCRC, providing valuable insights into routine first-line treatment practices for these patients. The data highlight the intrinsic aggressiveness of this disease subgroup, confirming results from previous real-world studies and clinical trials, and stressing the urgent need for more effective treatment options in this setting.
Collapse
|
37
|
Shah SSA, Saddique U, Khan MA, Khan S. Molecular epidemiology and phylogenetic analysis of Tams I gene of Theileria annulata in Khyber Pakhtunkhwa, Pakistan. Pol J Vet Sci 2022; 25:625-629. [PMID: 36649115 DOI: 10.24425/pjvs.2022.143543] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Theileriosis is a hemoparasitic disease that affects a wide range of different animal species and is caused by various species of Theileria. This study aimed to determine the molecular epidemiology of Theileria annulata through microscopy and PCR, in crossbred cattle in some districts of Khyber Pakhtunkhwa, Pakistan. For this study, a total of 384 blood samples were collected from cattle in the Peshawar (n=120), Charsadda (n=94), Nowshera (n=84), and Swabi (n=86) districts. Microscopy and PCR were used to determine the overall prevalence of theileriosis, which was found to be 15.8 and 22.6%, respectively. Theileria annulata was detected in blood samples through PCR in the study area, and the target gene i.e., Tams 1, of positive samples was sequenced. The sequences in the current study revealed high sequence homology (ranging from 96 to 100%) with Tams 1 sequences of neighboring countries present in the NCBI database. Season, breed, age, and sex were found to be important risk factors among the several risk factors examined, whereas, among different clinical manifestations, lymphadenopathy showed a strong association with theileriosis. According to Cohen's kappa and ROC analysis, microscopy was proven to be a fair diagnostic test for detecting theileriosis in cattle, and may be used in combination with molecular techniques for screening a large number of animals.
Collapse
|
38
|
Copley PC, Tadross D, Salloum N, Woodfield J, Edlmann E, Poon M, Khan S, Brennan PM. A systematic review identifying outcome measures used in evaluating adults sustaining cervical spine fractures. EUROPEAN SPINE JOURNAL : OFFICIAL PUBLICATION OF THE EUROPEAN SPINE SOCIETY, THE EUROPEAN SPINAL DEFORMITY SOCIETY, AND THE EUROPEAN SECTION OF THE CERVICAL SPINE RESEARCH SOCIETY 2022; 31:3365-3377. [PMID: 36063214 DOI: 10.1007/s00586-022-07369-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 08/22/2022] [Accepted: 08/25/2022] [Indexed: 12/14/2022]
Abstract
OBJECTIVE To assess the outcome measures used in studies investigating cervical spine fractures in adults, with or without associated spinal cord injury, to inform development of a core outcome set. METHODS Medline, Embase and Scopus were searched for relevant studies until May 28, 2022, without a historic limit on study date. Study characteristics, population characteristics and outcomes reported were extracted and analyzed. RESULTS Our literature search identified 536 studies that met criteria for inclusion, involving 393,266 patients. Most studies were single center (87.3%), retrospective studies (88.9%) and involved a median of 40 patients (range 6-167,278). Treatments assessed included: surgery (55.2%), conservative (6.2%), halo immobilization (4.9%), or a mixture (33.2%). Median study duration was 84 months (range 3-564 months); the timing of clinical and/or radiological follow-up assessment after injury was reported in 56.7%. There was significant heterogeneity in outcomes used, with 79 different reported outcomes measures. Differences in use were identified between smaller/larger, retro-/prospective and single/multicenter cohorts. Over time, the use of radiological outcomes has declined with greater emphasis on patient-reported outcome measures (PROMs). Studies of conservative management were more likely to detail PROMs and mortality, whereas surgical studies reported Frankel/ASIA grade, radiological fusion, complication rates, duration of hospital stay and re-operation rates more frequently. In studies assessing the elderly population (> 65 years), use of PROMs, mortality, hospital stay and discharge destination were more common, whereas fusion was reported less often. Response rates for outcome assessments were lower in studies assessing elderly patients, and studies using PROMs. CONCLUSIONS We have classified the various outcome measures used for patients with cervical spine fractures based on the COMET outcome taxonomy. We also described the contexts in which different outcomes are more commonly employed to help guide decision-making when designing future research endeavors.
Collapse
|
39
|
Moghaddam H, Khan N, Tan B, Khan S. Consumer attitude toward Halal food in the case of the United Kingdom: the role
of product attributes and marketing stimuli. FOOD RESEARCH 2022. [DOI: 10.26656/fr.2017.6(6).861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
The Halal market in the United Kingdom is worth $4.5 billion and is anticipated to grow
at a rate of 5% each year. In the United Kingdom, there is a growing demand for Halal
food, which has resulted in the formation of various unregulated Halal Certification
Bodies. In the halal food market, the problem of halal authenticity has recently become a
serious concern. The purpose of the paper was to determine the effect of product attributes
and marketing stimuli on customer attitudes toward halal food among Muslim customers
in the U.K. A cross-sectional study was adopted for this study. The sample of the study
included the Muslim customers who have consumed halal food in the U.K. The authors
used a survey method to collect the quantitative data. A total of 384 responses were
received and data were analysed using SPSS. The findings of the study revealed that
product attributes such as country of origin have a significantly greater influence on the
customer attitude towards halal food compared to other product attributes. The findings
further showed that marketing stimuli such as sales’ location impact on customer attitude
however advertisement did not have any impact on customer attitude towards halal food.
The finding held perspectives from Muslim customers in the U.K and contributes to the
stimulus-organism-response theory by incorporating product attributes and marketing as
stimulus factors that affect the internal psychological state i.e., customer’s attitude in the
case of the U.K. The implication of this study was to recommend Halal enterprises import
halal food from Islamic countries for U.K customers, research the strategic location and
select the hypermarkets, that handle halal food with care.
Collapse
|
40
|
Moody JD, Pollock BB, Sio H, Strozzi DJ, Ho DDM, Walsh CA, Kemp GE, Lahmann B, Kucheyev SO, Kozioziemski B, Carroll EG, Kroll J, Yanagisawa DK, Angus J, Bachmann B, Bhandarkar SD, Bude JD, Divol L, Ferguson B, Fry J, Hagler L, Hartouni E, Herrmann MC, Hsing W, Holunga DM, Izumi N, Javedani J, Johnson A, Khan S, Kalantar D, Kohut T, Logan BG, Masters N, Nikroo A, Orsi N, Piston K, Provencher C, Rowe A, Sater J, Skulina K, Stygar WA, Tang V, Winters SE, Zimmerman G, Adrian P, Chittenden JP, Appelbe B, Boxall A, Crilly A, O'Neill S, Davies J, Peebles J, Fujioka S. Increased Ion Temperature and Neutron Yield Observed in Magnetized Indirectly Driven D_{2}-Filled Capsule Implosions on the National Ignition Facility. PHYSICAL REVIEW LETTERS 2022; 129:195002. [PMID: 36399755 DOI: 10.1103/physrevlett.129.195002] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Accepted: 09/26/2022] [Indexed: 06/16/2023]
Abstract
The application of an external 26 Tesla axial magnetic field to a D_{2} gas-filled capsule indirectly driven on the National Ignition Facility is observed to increase the ion temperature by 40% and the neutron yield by a factor of 3.2 in a hot spot with areal density and temperature approaching what is required for fusion ignition [1]. The improvements are determined from energy spectral measurements of the 2.45 MeV neutrons from the D(d,n)^{3}He reaction, and the compressed central core B field is estimated to be ∼4.9 kT using the 14.1 MeV secondary neutrons from the D(T,n)^{4}He reactions. The experiments use a 30 kV pulsed-power system to deliver a ∼3 μs current pulse to a solenoidal coil wrapped around a novel high-electrical-resistivity AuTa_{4} hohlraum. Radiation magnetohydrodynamic simulations are consistent with the experiment.
Collapse
|
41
|
Khan S, Narayanan M, Olcott P, Oderinde O, Bal G, Schmall J, Xu S, Voronenko Y, Shao L, Kuduvalli G, Surucu M. Robustness of Biology-Guided Radiotherapy Delivery to PET Biodistribution Changes within Target. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.2180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
42
|
de Jong MC, McNamara J, Winter L, Roskell D, Khan S, Mihai R. Risk of malignancy in thyroid nodules with indeterminate (THY3f) cytology. Ann R Coll Surg Engl 2022; 104:703-709. [PMID: 35446717 PMCID: PMC9685951 DOI: 10.1308/rcsann.2021.0358] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2023] Open
Abstract
BACKGROUND Fine-needle aspiration cytology (FNAC) is an integral part of thyroid nodule assessment. Nodules with an indeterminate cytology (THY3a-f) require formal histological assessment to confirm benign or malignant pathology. This study aimed to provide data for an evidence-based approach for management of patients with THY3f nodules. METHODS Retrospective review of patients who had a thyroid FNAC reported as suspicious of follicular neoplasm (THY3f) or showing atypia (THY3a) were identified, and clinical, operative and outcomes data were analysed. RESULTS Between 2018 and 2020, 200 patients (167F:33M, median age 51 years (range:18-86 years)) had a THY3f cytology. Most presented with a palpable nodule (n=104; 68.4%). Overall, 152 (76.0%;130F:23M) underwent surgery and 31 (20.4%) were found to have a thyroid carcinoma (22 follicular carcinomas, 7 papillary carcinomas, 1 medullary thyroid carcinoma and 1 metastatic renal carcinoma). An additional incidental carcinoma (size: 0.7-13mm) was found in seven (4.6%). Among those with cancer, a completion thyroidectomy and radioactive iodine treatment was indicated in nine (<6% of the entire cohort). Previously suggested risk factors for malignancy, eg male gender, large tumour size (>4cm) or age, were not found to be associated with increased risk. During the same period, THY3a cytology was reported in 53 patients, of whom 29 underwent diagnostic surgery and 4 patients were found to have a thyroid cancer (follicular, n=3 and medullary, n=1). CONCLUSION One in five patients with features suspicious of a follicular neoplasm (THY3f) has a thyroid carcinoma. This risk is much lower for THY3a. This study reinforces the current recommendation for thyroid surgery in all patients with a reliable THY3f cytology, as no further stratifying risk factors could be identified.
Collapse
|
43
|
Khan K, Abdulelah Z, Murad S, Hsu YUKAI, Leung J, Shahid F, Khan S. Intracoronary Imaging in left main stent percutaneous coronary intervention has a clear survival benefit particularly in more complex patients. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Left Main Stem Disease (LMS) is prognostically important coronary artery disease that is managed either with coronary artery bypass surgery (CABG) or percutaneous coronary intervention (PCI). Use of intracoronary imaging (ICI) modalities such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) have been shown to improve outcomes with PCI revascularization.
The primary objective of this study was to evaluate the impact of ICI on outcomes following LMS PCI.
Methods
Retrospective observation study of 498 (5.1% of all PCI cases) patients who had undergone LMS PCI at our tertiary primary PCI centre hospital over a 11-year period between July 2010-July 2021. Data was collected from electronic medical records. Follow-up was also obtained through linkage with the Office of National Statistics.
Results
The mean age at the time of enrolment was 70.7±11.5 years. Majority of the patients were male 351 (70.5%). 353 (70.9%) of cases had acute coronary syndrome (ACS) presentation while the remainder were elective procedures. Mean follow-up duration was 3.75±3.06 years. Survival calculated by Kaplan-Meier was 70%. 87 patients (17.5%) deceased during first year of enrolment. 344 (69.1%) patients had ICI, with IVUS in 316 (63.5%) and OCT in 28 (5.6%) patients. IVUS comprised 91.9% of ICI procedures. Protected LMS (OR 0.175, 95% CI: 0.037–0.833, P-value=0.029) and the use of left ventricular mechanical support device (OR 0.324, 95% CI: 0.122–0.859, P-value=0.024) were associated with decreased odds of undergoing an ICI.
Patients undergoing ICI had significantly better survival compared to those without ICI (HR: 0.54, P<0.001). Moreover, OCT showed significantly better survival compared with IVUS (HR: 0.181, P=0.017). Use of ICI was associated with better survival in patients who had Rotablation (HR: 0.455, 95% CI: 0.232–0.892, P=0.022), ACS (HR: 0.523, 95% CI: 0.383–0.714, P<0.001) or comorbidities of diabetes and stroke (HR: 0.551, 95% CI: 0.337–0.807, P=0.002).
Conclusion
ICI in LMS PCI has a significant survival benefit in our dataset. This is especially the case in patients presenting with ACS, those with comorbidities of Diabetes mellitus and stroke and those undergoing rotablation.
Funding Acknowledgement
Type of funding sources: None.
Collapse
|
44
|
Khan S, Jaafar A, Rukayadi Y. Antibacterial activity of asam gelugur (Garcinia atroviridis Griff) fruit extract
against foodborne pathogens and its effect on microbial population in raw
chicken. FOOD RESEARCH 2022. [DOI: 10.26656/fr.2017.6(5).330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Foodborne illness has a major impact on public health and is a major concern worldwide.
The awareness about foodborne pathogens has increased among consumers because of
their significant impact on public health. Moreover, research on safe natural plant products
possessing antimicrobial activities against foodborne pathogens is vital because many
consumers prefer natural compounds to synthetic ones. This study aimed to determine the
antibacterial activity of Garcinia atroviridis Griff against foodborne pathogens and to
evaluate the effect of the fruit extract in the microbial population in raw chicken meat at
different concentrations and temperatures during storage. The antibacterial activity of G.
atroviridis Griff was assessed using disc diffusion assay (DDA), minimum inhibitory
concentration (MIC) and minimum bactericidal concentration (MBC). The DDA results
showed that the inhibition zone of the extract ranged from 6.50±0.50 to 11.00±0.00 mm.
The minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations
(MBC) values of the extract ranged from 3.13 to 25.00 mg/mL and 6.25 to 25.00 mg/mL,
respectively. G. atroviridis Griff maintained its antibacterial activity after being treated
with different temperatures (4˚C, 25˚C, 60˚C and 80˚C) and various pH ranges (pH 3.0,
7.0, and 9.0). A 5.00% concentration of extract can reduce the microbial population in the
raw chicken and maintain its microbiological quality with longer exposure within 21 days
in storage conditions at chiller and freezer temperature. The findings showed that the asam
gelugur extract might be used as a natural alternative preservative for reducing the
microbial population in raw chicken and maintaining its microbiological quality during
storage prior to cooking.
Collapse
|
45
|
Acharya S, Adamová D, Adler A, Adolfsson J, Aglieri Rinella G, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn S, Ahuja I, Akbar Z, Akindinov A, Al-Turany M, Alam S, Aleksandrov D, Alessandro B, Alfanda H, Alfaro Molina R, Ali B, Ali Y, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alocco G, Alt T, Altsybeev I, Anaam M, Andrei C, Andreou D, Andronic A, Anguelov V, Antinori F, Antonioli P, Anuj C, Apadula N, Aphecetche L, Appelshäuser H, Arcelli S, Arnaldi R, Arsene I, Arslandok M, Augustinus A, Averbeck R, Aziz S, Azmi M, Badalà A, Baek Y, Bai X, Bailhache R, Bailung Y, Bala R, Balbino A, Baldisseri A, Balis B, Banerjee D, Banoo Z, Barbera R, Barioglio L, Barlou M, Barnaföldi G, Barnby L, Barret V, Bartels C, Barth K, Bartsch E, Baruffaldi F, Bastid N, Basu S, Batigne G, Battistini D, Batyunya B, Bauri D, Bazo Alba J, Bearden I, Beattie C, Becht P, Belikov I, Bell Hechavarria A, Bellini F, Bellwied R, Belokurova S, Belyaev V, Bencedi G, Beole S, Bercuci A, Berdnikov Y, Berdnikova A, Bergmann L, Besoiu M, Betev L, Bhaduri P, Bhasin A, Bhat I, Bhat M, Bhattacharjee B, Bhattacharya P, Bianchi L, Bianchi N, Yamaguchi Y, Yamakawa K, Yang S, Yano S, Yin Z, Yoo IK, Yoon J, Yuan S, Yuncu A, Zaccolo V, Bielčík J, Zampolli C, Zanoli H, Zanone F, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zhalov M, Zhang B, Zhang S, Bielčíková J, Zhang X, Zhang Y, Zherebchevskii V, Zhi Y, Zhigareva N, Zhou D, Zhou Y, Zhu J, Zhu Y, Zinovjev G, Biernat J, Zurlo N, Bilandzic A, Biro G, Biswas S, Blair J, Blau D, Blidaru M, Blume C, Boca G, Bock F, Bogdanov A, Boi S, Bok J, Boldizsár L, Bolozdynya A, Bombara M, Bond P, Bonomi G, Borel H, Borissov A, Bossi H, Botta E, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruno G, Buckland M, Budnikov D, Buesching H, Bufalino S, Bugnon O, Buhler P, Buthelezi Z, Butt J, Bylinkin A, Bysiak S, Cai M, Caines H, Caliva A, Calvo Villar E, Camacho J, Camacho R, Camerini P, Canedo F, Carabas M, Carnesecchi F, Caron R, Castillo Castellanos J, Casula E, Catalano F, Ceballos Sanchez C, Chakaberia I, Chakraborty P, Chandra S, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Chavez T, Cheng T, Cheshkov C, Cheynis B, Chibante Barroso V, Chinellato D, Cho S, Chochula P, Christakoglou P, Christensen C, Christiansen P, Chujo T, Cicalo C, Cifarelli L, Cindolo F, Ciupek M, Clai G, Cleymans J, Colamaria F, Colburn J, Colella D, Collu A, Colocci M, Concas M, Conesa Balbastre G, Conesa del Valle Z, Contin G, Contreras J, Coquet M, Cormier T, Cortese P, Cosentino M, Costa F, Costanza S, Crochet P, Cruz-Torres R, Cuautle E, Cui P, Cunqueiro L, Dainese A, Danisch M, Danu A, Das P, Das P, Das S, Dash S, De Caro A, de Cataldo G, De Cilladi L, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Martin C, De Pasquale S, Deb S, Degenhardt H, Deja K, Del Grande R, Dello Stritto L, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diaz R, Dietel T, Ding Y, Divià R, Dixit D, Djuvsland Ø, Dmitrieva U, Do J, Dobrin A, Dönigus B, Dubey A, Dubla A, Dudi S, Dupieux P, Durkac M, Dzalaiova N, Eder T, Ehlers R, Eikeland V, Eisenhut F, Elia D, Erazmus B, Ercolessi F, Erhardt F, Erokhin A, Ersdal M, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fan W, Fantoni A, Fasel M, Fecchio P, Feliciello A, Feofilov G, Fernández Téllez A, Ferrero A, Ferretti A, Feuillard V, Figiel J, Filova V, Finogeev D, Fionda F, Fiorenza G, Flor F, Flores A, Foertsch S, Fokin S, Fragiacomo E, Frajna E, Francisco A, Fuchs U, Funicello N, Furget C, Furs A, Gaardhøje J, Gagliardi M, Gago A, Gal A, Galvan C, Ganoti P, Garabatos C, Garcia J, Garcia-Solis E, Garg K, Gargiulo C, Garibli A, Garner K, Gasik P, Gauger E, Gautam A, Gay Ducati M, Germain M, Ghosh S, Giacalone M, Gianotti P, Giubellino P, Giubilato P, Glaenzer A, Glässel P, Glimos E, Goh D, Gonzalez V, González-Trueba L, Gorbunov S, Gorgon M, Görlich L, Gotovac S, Grabski V, Graczykowski L, Greiner L, Grelli A, Grigoras C, Grigoriev V, Grigoryan S, Grosa F, Grosse-Oetringhaus J, Grosso R, Grund D, Guardiano G, Guernane R, Guilbaud M, Gulbrandsen K, Gunji T, Guo W, Gupta A, Gupta R, Guzman S, Gyulai L, Habib M, Hadjidakis C, Haidenbauer J, Hamagaki H, Hamid M, Hannigan R, Haque M, Harlenderova A, Harris J, Harton A, Hasenbichler J, Hassan H, Hatzifotiadou D, Hauer P, Havener L, Heckel S, Hellbär E, Helstrup H, Herman T, Herrera Corral G, Herrmann F, Hetland K, Heybeck B, Hillemanns H, Hills C, Hippolyte B, Hofman B, Hohlweger B, Honermann J, Hong G, Horak D, Hornung S, Horzyk A, Hosokawa R, Hou Y, Hristov P, Hughes C, Huhn P, Huhta L, Hulse C, Humanic T, Hushnud H, Husova L, Hutson A, Hyodo T, Iddon J, Ilkaev R, Ilyas H, Inaba M, Innocenti G, Ippolitov M, Isakov A, Isidori T, Islam M, Ivanov M, Ivanov V, Izucheev V, Jablonski M, Jacak B, Jacazio N, Jacobs P, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska M, Jalotra A, Janik M, Janson T, Jercic M, Jevons O, Jimenez A, Jonas F, Jones P, Jowett J, Jung J, Jung M, Junique A, Jusko A, Kabus M, Kaewjai J, Kalinak P, Kalteyer A, Kalweit A, Kamiya Y, Kaplin V, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Kashyap V, Kazantsev A, Kebschull U, Keidel R, Keijdener D, Keil M, Ketzer B, Khan A, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Kileng B, Kim B, Kim C, Kim D, Kim E, Kim J, Kim J, Kim J, Kim J, Kim M, Kim S, Kim T, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kitowski J, Klay J, Klein J, Klein S, Klein-Bösing C, Kleiner M, Klemenz T, Kluge A, Knospe A, Kobdaj C, Kollegger T, Kondratyev A, Kondratyeva N, Kondratyuk E, Konig J, Konigstorfer S, Konopka P, Kornakov G, Koryciak S, Kotliarov A, Kovalenko O, Kovalenko V, Kowalski M, Králik I, Kravčáková A, Kreis L, Krivda M, Krizek F, Krizkova Gajdosova K, Kroesen M, Krüger M, Krupova D, Kryshen E, Krzewicki M, Kučera V, Kuhn C, Kuijer P, Kumaoka T, Kumar D, Kumar L, Kumar N, Kundu S, Kurashvili P, Kurepin A, Kurepin A, Kuryakin A, Kushpil S, Kvapil J, Kweon M, Kwon J, Kwon Y, La Pointe S, La Rocca P, Lai Y, Lakrathok A, Lamanna M, Langoy R, Larionov P, Laudi E, Lautner L, Lavicka R, Lazareva T, Lea R, Lehrbach J, Lemmon R, León Monzón I, Lesch M, Lesser E, Lettrich M, Lévai P, Li X, Li X, Lien J, Lietava R, Lim B, Lim S, Lindenstruth V, Lindner A, Lippmann C, Liu A, Liu D, Liu J, Lofnes I, Loginov V, Loizides C, Loncar P, Lopez J, Lopez X, López Torres E, Luhder J, Lunardon M, Luparello G, Ma Y, Maevskaya A, Mager M, Mahmoud T, Maire A, Malaev M, Malik N, Malik Q, Malik S, Malinina L, Mal’Kevich D, Mallick D, Mallick N, Mandaglio G, Manko V, Manso F, Manzari V, Mao Y, Margagliotti G, Margotti A, Marín A, Markert C, Marquard M, Martin N, Martinengo P, Martinez J, Martínez M, Martínez García G, Masciocchi S, Masera M, Masoni A, Massacrier L, Mastroserio A, Mathis A, Matonoha O, Matuoka P, Matyja A, Mayer C, Mazuecos A, Mazzaschi F, Mazzilli M, Mdhluli J, Mechler A, Melikyan Y, Menchaca-Rocha A, Meninno E, Menon A, Meres M, Mhlanga S, Miake Y, Micheletti L, Migliorin L, Mihaylov D, Mikhaylov K, Mishra A, Miśkowiec D, Modak A, Mohanty A, Mohanty B, Mohisin Khan M, Molander M, Moravcova Z, Mordasini C, Moreira De Godoy D, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Mudnic E, Mühlheim D, Muhuri S, Mulligan J, Mulliri A, Munhoz M, Munzer R, Murakami H, Murray S, Musa L, Musinsky J, Myrcha J, Naik B, Nair R, Nandi B, Nania R, Nappi E, Nassirpour A, Nath A, Nattrass C, Neagu A, Negru A, Nellen L, Nesbo S, Neskovic G, Nesterov D, Nielsen B, Nielsen E, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Noh S, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Ogino M, Ohlson A, Ohnishi A, Okorokov V, Oleniacz J, Oliveira Da Silva A, Oliver M, Onnerstad A, Oppedisano C, Ortiz Velasquez A, Osako T, Oskarsson A, Otwinowski J, Oya M, Oyama K, Pachmayer Y, Padhan S, Pagano D, Paić G, Palasciano A, Panebianco S, Park J, Parkkila J, Pathak S, Patra R, Paul B, Pei H, Peitzmann T, Peng X, Pereira L, Pereira Da Costa H, Peresunko D, Perez G, Perrin S, Pestov Y, Petráček V, Petrov V, Petrovici M, Pezzi R, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Płoskoń M, Planinic M, Pliquett F, Poghosyan M, Polichtchouk B, Politano S, Poljak N, Pop A, Porteboeuf-Houssais S, Porter J, Pozdniakov V, Prasad S, Preghenella R, Prino F, Pruneau C, Pshenichnov I, Puccio M, Qiu S, Quaglia L, Quishpe R, Ragoni S, Rakotozafindrabe A, Ramello L, Rami F, Ramirez S, Rancien T, Raniwala R, Raniwala S, Räsänen S, Rath R, Ravasenga I, Read K, Redelbach A, Redlich K, Rehman A, Reichelt P, Reidt F, Reme-ness H, Rescakova Z, Reygers K, Riabov A, Riabov V, Richert T, Richter M, Riegler W, Riggi F, Ristea C, Rodríguez Cahuantzi M, Røed K, Rogalev R, Rogochaya E, Rogoschinski T, Rohr D, Röhrich D, Rojas P, Rojas Torres S, Rokita P, Ronchetti F, Rosano A, Rosas E, Rossi A, Roy A, Roy P, Roy S, Rubini N, Rueda O, Ruggiano D, Rui R, Rumyantsev B, Russek P, Russo R, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Rzesa W, Saarimaki O, Sadek R, Sadovsky S, Saetre J, Šafařík K, Saha S, Saha S, Sahoo B, Sahoo P, Sahoo R, Sahoo S, Sahu D, Sahu P, Saini J, Sakai S, Salvan M, Sambyal S, Saramela T, Sarkar D, Sarkar N, Sarma P, Sarti V, Sas M, Schambach J, Scheid H, Schiaua C, Schicker R, Schmah A, Schmidt C, Schmidt H, Schmidt M, Schmidt M, Schmidt N, Schmier A, Schotter R, Schukraft J, Schwarz K, Schweda K, Scioli G, Scomparin E, Seger J, Sekiguchi Y, Sekihata D, Selyuzhenkov I, Senyukov S, Seo J, Serebryakov D, Šerkšnytė L, Sevcenco A, Shaba T, Shabanov A, Shabetai A, Shahoyan R, Shaikh W, Shangaraev A, Sharma A, Sharma D, Sharma H, Sharma M, Sharma N, Sharma S, Sharma U, Shatat A, Sheibani O, Shigaki K, Shimomura M, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silva T, Silvermyr D, Simantathammakul T, Simonetti G, Singh B, Singh R, Singh R, Singh R, Singh V, Singhal V, Sinha T, Sitar B, Sitta M, Skaali T, Skorodumovs G, Slupecki M, Smirnov N, Snellings R, Soncco C, Song J, Songmoolnak A, Soramel F, Sorensen S, Sputowska I, Stachel J, Stan I, Steffanic P, Stiefelmaier S, Stocco D, Storehaug I, Storetvedt M, Stratmann P, Strazzi S, Stylianidis C, Suaide A, Suire C, Sukhanov M, Suljic M, Sultanov R, Sumberia V, Sumowidagdo S, Swain S, Szabo A, Szarka I, Tabassam U, Taghavi S, Taillepied G, Takahashi J, Tambave G, Tang S, Tang Z, Tapia Takaki J, Tapus N, Tarzila M, Tauro A, Tejeda Muñoz G, Telesca A, Terlizzi L, Terrevoli C, Tersimonov G, Thakur S, Thomas D, Tieulent R, Tikhonov A, Timmins A, Tkacik M, Toia A, Topilskaya N, Toppi M, Torales-Acosta F, Tork T, Torres Ramos A, Trifiró A, Triolo A, Tripathy S, Tripathy T, Trogolo S, Trubnikov V, Trzaska W, Trzcinski T, Tumkin A, Turrisi R, Tveter T, Ullaland K, Uras A, Urioni M, Usai G, Vala M, Valle N, Vallero S, van Doremalen L, van Leeuwen M, Vande Vyvre P, Varga D, Varga Z, Varga-Kofarago M, Vasileiou M, Vasiliev A, Vázquez Doce O, Vechernin V, Velure A, Vercellin E, Vergara Limón S, Vermunt L, Vértesi R, Verweij M, Vickovic L, Vilakazi Z, Villalobos Baillie O, Vino G, Vinogradov A, Virgili T, Vislavicius V, Vodopyanov A, Volkel B, Völkl M, Voloshin K, Voloshin S, Volpe G, von Haller B, Vorobyev I, Vozniuk N, Vrláková J, Wagner B, Wang C, Wang D, Weber M, Weelden R, Wegrzynek A, Wenzel S, Wessels J, Weyhmiller S, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems G, Windelband B, Winn M, Witt W, Wright J, Wu W, Wu Y, Xu R, Yadav A, Yalcin S. First study of the two-body scattering involving charm hadrons. Int J Clin Exp Med 2022. [DOI: 10.1103/physrevd.106.052010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
46
|
Martin Jimenez M, Lim E, Chavez Mac Gregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz F, Safin R, Kim SB, Schem C, Montero A, Khan S, Bandyopadhyay R, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Pérez-Moreno P, Sohn J. 211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
47
|
Naqvi S, Saleem Y, Ayaz A, Islam M, Riaz Z, Kazmi Z, Khan S, Riaz I. 1356P Socioeconomic vulnerabilities (SEV) and cancer-related mortality in United States (US): A cross-sectional analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
48
|
Goll JB, Jain A, Jensen TL, Assis R, Nakajima R, Jasinskas A, Coughlan L, Cherikh SR, Gelber CE, Khan S, Huw Davies D, Meade P, Stadlbauer D, Strohmeier S, Krammer F, Chen WH, Felgner PL. The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination. NPJ Vaccines 2022; 7:103. [PMID: 36042229 PMCID: PMC9427073 DOI: 10.1038/s41541-022-00524-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Accepted: 07/26/2022] [Indexed: 11/23/2022] Open
Abstract
Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full-length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and heterosubtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. The adjuvanted vaccine was also associated with the elicitation of stalk-directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers.
Collapse
|
49
|
Silva AE, Lyu A, Leat SJ, Khan S, Labreche T, Chan JCH, Li Q, Woo GC, Woo S, Cheong AMY, Thompson B. A differential effect of visual cortex tDCS on reading of English and Chinese in patients with central vision loss. Brain Stimul 2022; 15:1215-1217. [PMID: 36044975 DOI: 10.1016/j.brs.2022.08.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2022] [Revised: 08/13/2022] [Accepted: 08/23/2022] [Indexed: 11/02/2022] Open
|
50
|
Khan A, Rehman A, Omakobia E, Sood S, Khan S. 19 A Rare Case of Parapharyngeal Schwannoma Mimicking Peritonsillar Abscess in a Young Female Patient. Br J Surg 2022. [DOI: 10.1093/bjs/znac269.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Abstract
Introduction
Parapharyngeal Space (PPS) tumours are responsible for 0.5% of head and neck cancers. Presenting features can mimic peritonsillar abscess. A differential diagnosis of PPS tumour should therefore be considered in young, systemically well patients with resistant peritonsillar masses.
Aim
To report a rare case of parapharyngeal schwannoma in a fit and well adult female with a focus on investigations and optimal management.
Method
A 29-year-old, Caucasian female presented with a three-week history of a right sided oropharyngeal mass, odynophagia, and dysphonia. A stagnant clinical picture prompted further investigation with Magnetic Resonance Imaging (MRI). This demonstrated a 7cm right sided PPS mass arising from the deep lobe of the right parotid gland. Mass excision and partial, ipsilateral parotidectomy confirmed Schwannoma (neurilemoma).
Results & Discussion
Schwannomas account for a third of PPS tumours. Arising from neurological Schwann cells, they are often encapsulated, benign tumours which are characterised by slow and asymptomatic growth. Presentation often follows mass effects leading to dysphagia, odynophagia, and dysphonia. MRI and FNAC remain the gold standard in confirmation of diagnosis. Insensitivity to radiotherapy ensures that surgical resection is the mainstay of treatment and may utilise the transcervical, transparotid or transmandibular approach.
Conclusion
There is a significant degree of overlap in the epidemiology and presenting features of peritonsillar abscess and PPS tumours. In cases of treatment resistant, chronic peritonsillar masses a differential diagnosis of PPS tumour must therefore be excluded.
Collapse
|